Ownership and insider activity for Bolt Biotherapeutics, Inc. (BOLT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
Price
| Price | $3.35 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-10 | Berner Laura | A-Award | 5,000 | $22K |
| 2026-06-10 | LAPORTE KATHLEEN | A-Award | 5,000 | $22K |
| 2026-06-10 | Dupont Jakob | A-Award | 5,000 | $22K |
| 2026-06-10 | O'CALLAGHAN BRIAN | A-Award | 5,000 | $22K |
| 2026-06-10 | ONETTO NICOLE | A-Award | 5,000 | $22K |
| 2026-01-28 | Quinn William P. | A-Award | 20,000 | $134K |
| 2025-12-05 | Quinn William P. | P-Purchase | 125 | $576 |
| 2026-01-28 | Yonehiro Grant | A-Award | 10,000 | $67K |
| 2026-01-28 | Nemec Sarah | A-Award | 8,000 | $54K |
| 2025-12-05 | Nemec Sarah | P-Purchase | 125 | $576 |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.6M | $34.8M | $5.5M | $27.4M | $9.2M | $10.8M | $7.2M | $11.7M |
| Short-term Investments | 0 | 0 | $17.3M | $158.8M | $159.6M | $91.4M | $40.1M | $15.8M |
| Receivables | 0 | $300000 | 0 | $200000 | 0 | 0 | $1.2M | $973000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $14.1M | $35.9M | $25.4M | $189.2M | $172.7M | $105.7M | $50.8M | $30.3M |
| Property, Plant & Equipment | $1.4M | $11.5M | $16.4M | $30.6M | $28.5M | $24.1M | $24.9M | $20.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $16.0M | $48.4M | $46.5M | $307.7M | $227.8M | $159.8M | $99.6M | $56.7M |
| Accounts Payable | $892000 | $2.1M | $1.6M | $3.6M | $3.6M | $3.0M | $1.5M | $1.4M |
| Short-term Debt | 0 | 0 | 0 | $2.5M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.8M | $8.7M | $11.3M | $21.3M | $23.1M | $20.5M | $15.9M | $8.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $31.9M | $94.3M | $151.5M | $57.6M | $56.3M | $47.0M | $42.4M | $30.2M |
| Retained Earnings | -$17.2M | -$47.7M | -$108.4M | -$207.0M | -$295.1M | -$364.3M | -$427.4M | -$460.8M |
| Total Equity | -$15.9M | -$45.8M | -$104.9M | $250.1M | $171.5M | $112.7M | $57.2M | $26.5M |
| Total Debt | $40000 | $10.2M | $10.9M | $24.4M | $22.6M | $20.2M | $25.2M | $23.0M |
| Net Debt | -$13.6M | -$24.6M | -$12.0M | -$161.9M | -$146.3M | -$82.0M | -$22.1M | -$4.5M |
| Working Capital | $11.3M | $27.2M | $14.1M | $167.8M | $149.6M | $85.3M | $35.0M | $21.8M |
Financial Health
| Debt / Equity | 1.71 |
| Current Ratio | 2.61 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -12.58 |
Profitability
| Return on Equity | -125.92% |
| Return on Invested Capital | -67.72% |
| Return on Assets | -58.81% |
| Gross Margin | 95.68% |
| Operating Margin | -623.04% |
| Net Margin | -611.47% |
Related companies: AEON · CING · CLRB · EVGN · IMNN · INAB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of BOLT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks